iRhythm price target raised to $143 from $135 at Canaccord
The Fly

iRhythm price target raised to $143 from $135 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on iRhythm to $143 from $135 and keeps a Buy rating on the shares. The analyst said it seems the company has already seen solid traction in its next area of growth, the primary care segment, including announcing a nationwide agreement with One Medical and some other unnamed primary care networks.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on IRTC:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App